Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of pp60c-src in 60 different cell lines derived from human tumors.

Literature DB >> 7537173

Activity of pp60c-src in 60 different cell lines derived from human tumors.

Abstract

The activity of the protein tyrosine kinase pp60c-src was determined for each of the 60 human cell lines in the panel used by the National Cancer Institute for the random screening of potential anticancer drugs. The leukemia, lymphoma, melanoma, and small-cell lung cancer derived cell lines had low pp60c-src activity. Surprisingly, non-small-cell lung and ovarian cell lines had a median pp60c-src activity which was greater than that of the panel of cells representing colon cancer, which is most often associated with elevated pp60c-src activity. This data defines homologous cell lines which contain low and high pp60c-src activity which will aid attempts to understand the role of this enzyme in human cancer.

Entities: Disease Species

Mesh：

Substances：

Year: 1994 PMID： 7537173

Source DB: PubMed Journal: Cancer Biochem Biophys ISSN： 0305-7232

Keyword Cloud
Cited

20 in total

1. Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues.

Authors: Amy L McDoniels-Silvers; Gary D Stoner; Ronald A Lubet; Ming You
Journal: Neoplasia Date: 2002 Mar-Apr Impact factor: 5.715

2. SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.

Authors: Rui Zheng; Seiji Yano; Yuka Matsumori; Emiko Nakataki; Hiroaki Muguruma; Masanori Yoshizumi; Saburo Sone
Journal: Clin Exp Metastasis Date: 2005 Impact factor: 5.150

3. Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.

Authors: Angeles Alvarez Secord; Deanna Teoh; Jingquan Jia; Andrew B Nixon; Lisa Grace; David J Adams; Susan K Murphy
Journal: Int J Gynecol Cancer Date: 2014-02 Impact factor: 3.437

4. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.

Authors: Deanna Teoh; Tina A Ayeni; Jennifer M Rubatt; David J Adams; Lisa Grace; Mark D Starr; William T Barry; Andrew Berchuck; Susan K Murphy; Angeles Alvarez Secord
Journal: Gynecol Oncol Date: 2011-01-03 Impact factor: 5.482

Review 5. Src family kinases and paclitaxel sensitivity.

Authors: Xiao-Feng Le; Robert C Bast
Journal: Cancer Biol Ther Date: 2011-08-15 Impact factor: 4.742

6. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.

Authors: Liz Y Han; Charles N Landen; Jose G Trevino; Jyotsnabaran Halder; Yvonne G Lin; Aparna A Kamat; Tae-Jin Kim; William M Merritt; Robert L Coleman; David M Gershenson; William C Shakespeare; Yihan Wang; Raji Sundaramoorth; Chester A Metcalf; David C Dalgarno; Tomi K Sawyer; Gary E Gallick; Anil K Sood
Journal: Cancer Res Date: 2006-09-01 Impact factor: 12.701

Activity of pp60c-src in 60 different cell lines derived from human tumors.

1. Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues.

2. SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.

3. Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.

4. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.

Review 5. Src family kinases and paclitaxel sensitivity.

6. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.

7. Differing Src signaling levels have distinct outcomes in Drosophila.

8. Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors.

9. mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src.

10. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.